Earnings GrowthIn FY26, Medtronic will contend with ongoing FX pressures, dilutive new product/capital rollouts, and a slight tax headwind which may limit sustainable high-single-digit EPS growth.
Financial PerformanceMedtronic faces challenges such as inflation, higher labor costs, and higher material costs, which have led to a decline in net profits and profit margins.
Market CompetitionThe growing popularity of GLP-1 drugs could significantly impact Medtronic's insulin pump sales, with a risk of losing 50% of its market share.